Here's Why CRISPR Stocks Fell in January
Spurred by promising clinical results in an important trial, each of the three major CRISPR stocks had a great performance in the second half of 2019. Unfortunately, they didn't keep the momentum going in the first month of 2020.
Shares of Intellia Therapeutics (NASDAQ: NTLA) fell 18.8% in January, according to data provided by S&P Global Market Intelligence. That was followed by a 14.7% loss for shares of CRISPR Therapeutics (NASDAQ: CRSP) and a 10.7% tumble for shares of Editas Medicine (NASDAQ: EDIT).
While each has recovered some ground in the first week of February, this trio of pharma stocks is no stranger to volatility. Investors should probably expect that to continue as clinical programs advance in 2020.
Source Fool.com
